FDA-Indexed. Pharmaceutical Grade. Simple to Order and Administer.

New Ethiqa XR from Fidelis Pharmaceuticals is the first and only pharmaceutical grade extended-release buprenorphine proven effective in reducing pain for lab mice and rats up to 72 hours after administration of just one injection.

Pure Pain Relief

Coming soon through distributors…
Ethiqa XR will offer:

  • Simple ordering
  • Low-viscosity formula
  • Easy administration

An Ethical Imperative
Effective pain management for laboratory animals is an essential need in today’s research. Learn more about industry association guidelines.

  • Fidelis Pharmaceuticals, the U.S.-based manufacturer of Ethiqa XR, is deeply committed to improving animal welfare with innovative new solutions for reducing discomfort in lab animals.
  • The Fidelis leadership team supports the foremost veterinary, laboratory research, and human healthcare industry associations and initiatives, including:

Ethiqa XR is the only pharmaceutical grade buprenorphine formulation FDA-indexed for use as mouse and rat analgesia.

View Ethiqa XR Product Labeling
View FDA-Indexed Listing (scroll to Fidelis 900-014)

Important Safety Information


Abuse Potential

This formulation contains buprenorphine, a high-concentration (1.3 mg/mL) opioid agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. The high concentration may be a particular target for human abuse. Buprenorphine has opioid properties that in humans may lead to dependence of the morphine type. Abuse of buprenorphine may lead to low or moderate physical dependence or high psychological dependence. The risk of abuse by humans should be considered when storing, administering, and disposing. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (suicidal depression). Because of human safety risks, this drug should be used only with veterinary supervision.

Do not dispense this formulation.

Life-Threatening Respiratory Depression

The concentration of buprenorphine is 1.3 mg/mL. Respiratory depression, including fatal cases, may occur with abuse of this formulation. There are additive CNS depressant efects when used with alcohol, other opioids, or illicit drugs that cause central nervous system depression. Because of the potential for adverse reactions associated with accidental injection, this formulation should only be administered by a veterinarian or laboratory staf trained in the handling of potent opioids.

Please see full Ethiqa XR Prescribing Information for additional Important Safety Information.